Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug 1;14(4):651-654.
doi: 10.21037/hbsn-2025-250. Epub 2025 Jul 25.

Empagliflozin for non-diabetic metabolic dysfunction-associated steatotic liver disease: a promising therapeutic agent in transition

Mohamed El-Kassas  1   2 , Hongqun Liu  3 , Samuel S Lee  3
Affiliations
Editorial

Empagliflozin for non-diabetic metabolic dysfunction-associated steatotic liver disease: a promising therapeutic agent in transition

Mohamed El-Kassas et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Liver; empagliflozin; magnetic resonance imaging-proton density fat fraction (MRI-PDFF); metabolic dysfunction-associated steatotic liver disease (MASLD); sodium-glucose co-transporter-2 (SGLT2).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2025-250/coif). S.S.L. reports consulting fees from Abbvie, Gilead, Mallinckrodt, Grifols, and Jazz; honoraria from Abbvie and Gilead; participation on Data Safety Monitoring Boards for Abbvie and Jazz; and stock options in Oncoustics Corp. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79:1542-56. 10.1016/j.jhep.2023.06.003 - DOI - PubMed
    1. Feng G, Targher G, Byrne CD, et al. Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep 2025;7:101271. 10.1016/j.jhepr.2024.101271 - DOI - PMC - PubMed
    1. El-Kassas M, Cabezas J, Coz PI, et al. Nonalcoholic Fatty Liver Disease: Current Global Burden. Semin Liver Dis 2022;42:401-12. 10.1055/a-1862-9088 - DOI - PubMed
    1. El-Kassas M, Alswat K. Editorial: Emerging therapeutic approaches for non-alcoholic fatty liver disease. Front Med (Lausanne) 2024;11:1437385. 10.3389/fmed.2024.1437385 - DOI - PMC - PubMed
    1. Younossi ZM, Zelber-Sagi S, Lazarus JV, et al. Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Gastroenterology 2025. [Epub ahead of print]. doi: . 10.1053/j.gastro.2025.02.044 - DOI - PubMed